Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on...
February 05, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
January 21, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law...
January 13, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an...
January 06, 2025 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO,...
December 19, 2024 17:25 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024...
December 18, 2024 08:00 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...
December 13, 2024 16:58 ET | Source: ARS Pharmaceuticals, Inc.

ARSファーマシューティカルズ (ARS Pharmaceuticals)、neffy®の中国、日本、オーストラリアでの承認申請を発表

サンディエゴ発, Dec. 14, 2024 (GLOBE NEWSWIRE) -- アナフィラキシーに至る可能性のあるアレルギー反応から自身を守るための支援を目指すバイオ医薬品企業であるARSファーマシューティカルズ (ARS Pharmaceuticals, Inc.) (NASDAQ: SPRY)...
December 13, 2024 16:58 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy®

圣地亚哥, Dec. 14, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) 是一家生物制药公司，致力于帮助高风险患者和护理人员更好地保护患者免于可能导致过敏性休克的过敏反应。该公司今天宣布，其在中国、日本和澳大利亚的授权合作伙伴已在各自国家申请批准 2 毫克剂量的 neffy® （肾上腺素鼻喷雾剂）。 2...
December 12, 2024 14:32 ET | Source: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect...